# Sixth Street Specialty Lending, Inc.: financial statements, quarterly

TSLX · NYSE · CIK 1508655 · [Other](/sectors/other.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tslx.md) · [Financials](/companies/tslx/financials.md) · [Filings](/companies/tslx/filings.md) · [Insiders](/companies/tslx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tslx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [35.0](/filings/0000950170-23-058321.md) | [37.8 d](/filings/0000950170-24-015845.md) | [39.0](/filings/0000950170-24-051235.md) | [39.2](/filings/0000950170-24-088524.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.5](/filings/0000950170-24-121434.md) | [0.6 d](/filings/0000950170-25-019845.md) | [0.9](/filings/0000950170-24-051235.md) | [1.2](/filings/0000950170-24-088524.md) | [0.7](/filings/0000950170-24-121434.md) | [1.2 d](/filings/0000950170-25-019845.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [64.8](/filings/0001193125-26-048664.md) | [51.2](/filings/0001193125-26-048664.md) | [47.5](/filings/0000950170-25-061008.md) | [47.4](/filings/0000950170-25-100204.md) | [40.7](/filings/0001193125-25-264618.md) | [51.0](/filings/0001193125-26-048664.md) | [37.0](/filings/0001193125-26-206313.md) | [59.0](/filings/0001193125-26-332725.md) | [44.6](/filings/0001193125-25-264618.md) | [30.0](/filings/0001193125-26-048664.md) | [(26.0)](/filings/0001193125-26-206313.md) | [40.5](/filings/0001193125-26-332725.md) |
| Diluted EPS | $ per share | [0.74](/filings/0000950170-24-121434.md) | not reported | [0.53](/filings/0000950170-25-061008.md) | [0.51](/filings/0000950170-25-100204.md) | [0.44](/filings/0001193125-25-264618.md) | not reported | [0.39](/filings/0001193125-26-206313.md) | [0.63](/filings/0001193125-26-332725.md) | [0.47](/filings/0001193125-25-264618.md) | not reported | [(0.27)](/filings/0001193125-26-206313.md) | [0.43](/filings/0001193125-26-332725.md) |
| Basic EPS | $ per share | [0.74](/filings/0000950170-24-121434.md) | not reported | [0.53](/filings/0000950170-25-061008.md) | [0.51](/filings/0000950170-25-100204.md) | [0.44](/filings/0001193125-25-264618.md) | not reported | [0.39](/filings/0001193125-26-206313.md) | [0.63](/filings/0001193125-26-332725.md) | [0.47](/filings/0001193125-25-264618.md) | not reported | [(0.27)](/filings/0001193125-26-206313.md) | [0.43](/filings/0001193125-26-332725.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [29.9](/filings/0000950170-23-058321.md) | [25.2](/filings/0000950170-25-019845.md) | [35.9](/filings/0000950170-24-051235.md) | [34.6](/filings/0000950170-24-088524.md) | [29.7](/filings/0000950170-24-121434.md) | [27.3](/filings/0001193125-26-048664.md) | [47.3](/filings/0000950170-25-061008.md) | [39.2](/filings/0000950170-25-100204.md) | [83.2](/filings/0001193125-25-264618.md) | [19.7](/filings/0001193125-26-332725.md) | [29.2](/filings/0001193125-26-206313.md) | [194](/filings/0001193125-26-332725.md) |
| Total assets | $m | [3,174](/filings/0000950170-23-058321.md) | [3,344](/filings/0000950170-25-019845.md) | [3,452](/filings/0000950170-24-051235.md) | [3,387](/filings/0000950170-24-088524.md) | [3,530](/filings/0000950170-24-121434.md) | [3,582](/filings/0001193125-26-048664.md) | [3,499](/filings/0000950170-25-061008.md) | [3,416](/filings/0000950170-25-100204.md) | [3,509](/filings/0001193125-25-264618.md) | [3,422](/filings/0001193125-26-332725.md) | [3,393](/filings/0001193125-26-206313.md) | [3,543](/filings/0001193125-26-332725.md) |
| Total liabilities | $m | [1,688](/filings/0000950170-23-058321.md) | [1,847](/filings/0000950170-25-019845.md) | [1,870](/filings/0000950170-24-051235.md) | [1,788](/filings/0000950170-24-088524.md) | [1,933](/filings/0000950170-24-121434.md) | [1,975](/filings/0001193125-26-048664.md) | [1,897](/filings/0000950170-25-061008.md) | [1,798](/filings/0000950170-25-100204.md) | [1,890](/filings/0001193125-25-264618.md) | [1,814](/filings/0001193125-26-332725.md) | [1,850](/filings/0001193125-26-206313.md) | [1,995](/filings/0001193125-26-332725.md) |
| Long-term debt | $m | [1,623](/filings/0000950170-23-058321.md) | [1,780](/filings/0000950170-25-019845.md) | [1,804](/filings/0000950170-24-051235.md) | [1,713](/filings/0000950170-24-088524.md) | [1,870](/filings/0000950170-24-121434.md) | [1,901](/filings/0001193125-26-048664.md) | [1,845](/filings/0000950170-25-061008.md) | [1,727](/filings/0000950170-25-100204.md) | [1,834](/filings/0001193125-25-264618.md) | [1,743](/filings/0001193125-26-332725.md) | [1,803](/filings/0001193125-26-206313.md) | [1,925](/filings/0001193125-26-332725.md) |
| Shareholders' equity | $m | [1,486](/filings/0000950170-24-121434.md) | [1,496](/filings/0001193125-26-048664.md) | [1,582](/filings/0001193125-25-264618.md) | [1,599](/filings/0001193125-25-264618.md) | [1,597](/filings/0001193125-25-264618.md) | [1,608](/filings/0001193125-26-332725.md) | [1,601](/filings/0001193125-26-332725.md) | [1,618](/filings/0001193125-26-332725.md) | [1,620](/filings/0001193125-25-264618.md) | [1,608](/filings/0001193125-26-332725.md) | [1,543](/filings/0001193125-26-332725.md) | [1,549](/filings/0001193125-26-332725.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [36.7 d](/filings/0000950170-24-121434.md) | [(86.9) d](/filings/0001193125-26-048664.md) | [(65.5)](/filings/0000950170-25-061008.md) | [125 d](/filings/0000950170-25-100204.md) | [(74.5) d](/filings/0001193125-25-264618.md) | [(30.7) d](/filings/0001193125-26-048664.md) | [150](/filings/0001193125-26-206313.md) | [193 d](/filings/0001193125-26-332725.md) | [(15.6) d](/filings/0001193125-25-264618.md) | [74.1 d](/filings/0001193125-26-048664.md) | [(23.4)](/filings/0001193125-26-206313.md) | [68.3 d](/filings/0001193125-26-332725.md) |
| Dividends paid | $m | [39.4 d](/filings/0000950170-24-121434.md) | [40.6 d](/filings/0001193125-26-048664.md) | [43.3](/filings/0000950170-25-061008.md) | [42.2 d](/filings/0000950170-25-100204.md) | [42.5 d](/filings/0001193125-25-264618.md) | [40.6 d](/filings/0001193125-26-048664.md) | [43.2](/filings/0001193125-26-206313.md) | [42.6 d](/filings/0001193125-26-332725.md) | [42.5 d](/filings/0001193125-25-264618.md) | [41.9 d](/filings/0001193125-26-048664.md) | [39.0](/filings/0001193125-26-206313.md) | [34.1 d](/filings/0001193125-26-332725.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [79.5](/filings/0000950170-23-058321.md) | [81.4](/filings/0000950170-24-051235.md) | [84.2](/filings/0000950170-24-088524.md) | [87.3](/filings/0000950170-24-121434.md) | [89.0](/filings/0000950170-25-061008.md) | [92.7](/filings/0000950170-25-100204.md) | [93.0](/filings/0001193125-25-264618.md) | [93.7](/filings/0001193125-26-206313.md) | [94.0](/filings/0001193125-26-332725.md) | [94.2](/filings/0001193125-25-264618.md) | [94.7](/filings/0001193125-26-206313.md) | [95.0](/filings/0001193125-26-332725.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 95,343,139 at 2026-08-04, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332725.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.